Keywords
Endocrinology
Growth Hormone Secreting Pituitary Adenoma
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the characteristics of acromegaly. Bibliographic Review: Acromegaly is a rare endocrine disease associated with high levels of growth hormone and insulin-like factor I. Acromegaly is a rare disease with an annual incidence of four per million. The average age at diagnosis ranges from 40 to 50 years and the disease is typically diagnosed with a delay of 5 to 10 years and, if left untreated, is associated with significant morbidity and increased mortality. Final considerations: Acromegaly is an endocrine disease whose main symptoms are enlarged hands and feet, changes in facial appearance and headaches, in addition to being accompanied by comorbidities such as diabetes, cardiovascular diseases, respiratory disorders and increased incidence of neoplasms. Its treatment aims at controlling the biochemical markers of disease activity, GH and IGF-I, in addition to reducing symptoms and comorbidities and is mainly done through surgery in addition to the administration of somatostatin receptor ligands, dopamine agonists and GH receptors.
References
AKIROV A, et al. The Biochemical Diagnosis of Acromegaly. J Clin Med, 2021; 10(5): 1147.
AL DAHMANI K, et al. Clinical Presentation, Treatment, and Outcome of Acromegaly in the United Arab Emirates. Oman Med J, 2020; 35(5): e172.
ARLIEN-SOBORG MC, et al. Acromegaly. Ugeskr Laeger, 2018; 180(49): V09170637.
BOLANOWSKI M, et al. Editorial: Health-Related Complications of Acromegaly. Front Endocrinol (Lausanne), 2020; 11: 496.
BOLANOWSKI M, et al. Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan. Front Endocrinol (Lausanne), 2022; 13: 816426.
BRAY DP, et al. Surgery for acromegaly: Indications and goals. Front Endocrinol (Lausanne), 2022; 13: 924589.
DAL J, et al. Sex differences in acromegaly. Pol Arch Intern Med, 2022; 132(6): 16270.
DANILOWICZ K, et al. Acromegaly and thyroid cancer: analysis of evolution in a series of patients. Clin Diabetes Endocrinol, 2020; 6(1): 24.
ELBAUM M, et al. The real costs of acromegaly: analysis of different therapies. Endokrynol Pol, 2019; 70(1): 74-85.
FERRAÙ F, et al. Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment. Front Endocrinol (Lausanne), 2018; 9: 358.
FLESERIU M, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary, 2021; 24(1): 1-13.
GANOKROJ P, et al. Clinical characteristics and treatment outcomes in acromegaly, a retrospective single-center case series from Thailand. Pan Afr Med J, 2021; 40: 31.
HEIDARPOUR M, et al. Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review. J Res Med Sci, 2019; 24: 29.
GIUSTINA A, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord, 2020; 21(4): 667-678.
KHAN SA, et al. Prevalence of Comorbidities among Patients with Acromegaly. Pak J Med Sci, 2021; 37(7): 1758-1761.
KYRIAKAKIS N, et al. Management of persistent acromegaly following primary therapy: The current landscape in the UK. Endocrinol Diabetes Metab, 2020; 3(3): e00158.
LEONART LP, et al. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis. Value Health, 2018; 21(7): 874-880.
MAIA B, et al. Novel therapies for acromegaly. Endocr Connect, 2020; 9(12): 274-285.
OTANI D, et al. Acromegaly accompanied by diabetes mellitus and polycystic kidney disease. Endocr J, 2021; 68(1): 103-110.
ROLLA M, et al. Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center. Front Endocrinol (Lausanne), 2021;12: 642131.
RUCHALA M e WOLINSKI K. Health-Related Complications of Acromegaly-Risk of Malignant Neoplasms. Front Endocrinol (Lausanne), 2019; 10: 268.
SARKAR S e CHACKO AG. Surgery for Acromegaly. Neurol India, 2020; 68: 44-51.
TERZOLO M, et al. Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population? Eur J Endocrinol, 2020; 183(4): 1-13.
WANI AA. Acromegaly and Diabetes - A Hand in Glove Combination. Neurol India, 2020; 68(5): 1259-1260.
YAMAMOTO M e TAKAHASHI Y. Genetic and Epigenetic Pathogenesis of Acromegaly. Cancers (Basel), 2022; 14(16): 3861.
YANG H, et al. Advances in Research on the Cardiovascular Complications of Acromegaly. Front Oncol, 2021; 11: 640999.
ZAHR R e FLESERIU M. Updates in Diagnosis and Treatment of Acromegaly. Eur Endocrinol, 2018; 14(2): 57-61.